AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8934305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use detected through hair analysis
Number of subjects: 615
Study 1860135 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate
Number of subjects: 20
Study 1860135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6614419 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5-2 mg p.o. the evening before operation (Group 1)
Number of subjects: 128
Study 6614419 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.5-2 mg p.o. the evening before and the morning of operation (Group 2)
Number of subjects: 128
Study 6614419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 2-2.5 mg p.o. the same time as Group 2 (Group 3)
Number of subjects: 128
Study 6614419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg p.o. the evening before operation and pethidine 50-100 mg combined with promethazine 25 mg i.m. 60 min before surgery (Group 4)
Number of subjects: 128
Study 30914170 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of male provision
Number of subjects: 108
Study 27423222 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 21
Study 27423222 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 21
Study 26603558 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravitreal betamethasone injection (early-IVB)
Number of subjects: 97
Study 26603558 — intervention group
Group type: COMPARATOR
Intervention: Delayed intravitreal betamethasone injection (delayed-IVB)
Number of subjects: 97
Study 26603558 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-IVB
Number of subjects: 97
Study 26603558 — intervention group
Group type: COMPARATOR
Intervention: Delayed-IVB
Number of subjects: 97
Study 24374073 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin combined with radiotherapy
Number of subjects: 80
Study 24374073 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study 23529990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis extract (165 μmol artepillin C and 150 μmol other polyphenols per day for 3 months)
Number of subjects: 31
Study 23529990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis extract
Number of subjects: 31
Study 23529990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23529990 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative treatment prior to endoscopic biopsy
Number of subjects: 31
Study 19674427 — intervention group
Group type: EXPERIMENTAL
Intervention: Premier Hospital Quality Incentive Demonstration (PHQID) program
Number of subjects: 6723928
Study 18277517 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent context
Number of subjects: 0
Study 18277517 — intervention group
Group type: COMPARATOR
Intervention: Incoherent context
Number of subjects: 0
Study 18277517 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative local properties
Number of subjects: 0
Study 15741420 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic preparation of common allergens
Number of subjects: 40
Study 15741420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12212923 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine/indinavir (induction phase)
Number of subjects: 366
Study 12212923 — intervention group
Group type: COMPARATOR
Intervention: zidovudine/lamivudine (maintenance phase)
Number of subjects: 366
Study 12212923 — intervention group
Group type: COMPARATOR
Intervention: zidovudine/indinavir (maintenance phase)
Number of subjects: 366
Study 12212923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence of 80% or greater
Number of subjects: 366
Study 12212923 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence <80%
Number of subjects: 366
Study 12212923 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor adherence (two or more severe adverse events)
Number of subjects: 366
Study 9671428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.2 microg/kg/min)
Number of subjects: 12
Study 9671428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.5 microg/kg/min)
Number of subjects: 12
Study 9671428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (1.0 microg/kg/min)
Number of subjects: 12
Study 9671428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9671428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (all doses)
Number of subjects: 12
Study 9671428 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonioscopy
Number of subjects: 12
Study 8747563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) mivacurium 0.15 mg/kg with stable general anesthesia
Number of subjects: 36
Study 8747563 — intervention group
Group type: COMPARATOR
Intervention: Single bolus administration of mivacurium
Number of subjects: 36
Study 2468447 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin infusion
Number of subjects: 20
Study 2468447 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low MW hydroxyethyl starch (pentastarch) infusion
Number of subjects: 20
Study 2468447 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 796485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephacetrile (CEC)
Number of subjects: 101
Study 796485 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (CEZ)
Number of subjects: 101
Study 31299400 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex polypharmacy (use of ≥3 BD medications)
Number of subjects: 482
Study 31299400 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence
Number of subjects: 482
Study 31299400 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid social or generalized anxiety disorder
Number of subjects: 482
Study 31299400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder I vs. II
Number of subjects: 482
Study 29061630 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus biopsychosocial intervention
Number of subjects: 40
Study 29061630 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 25481791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus chemotherapy (paclitaxel and carboplatin)
Number of subjects: 162
Study 25481791 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel and carboplatin)
Number of subjects: 162
Study 25481791 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus chemotherapy
Number of subjects: 162
Study 23668681 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ciliary neurotrophic factor implant
Number of subjects: 133
Study 23668681 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ciliary neurotrophic factor implant
Number of subjects: 133
Study 23668681 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 133
Study 23668681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor treatment
Number of subjects: 133
Study 23668681 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 133
Study 21887905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam 40 mg
Number of subjects: 60
Study 21887905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19004023 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (32,000 men)
Number of subjects: 80000
Study 19004023 — intervention group
Group type: COMPARATOR
Intervention: Control arm (48,000 men)
Number of subjects: 80000
Study 19004023 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 80000
Study 16719196 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative relaxation training
Number of subjects: 49
Study 16719196 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative information
Number of subjects: 49
Study 15570646 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg po bid
Number of subjects: 43
Study 11529362 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (Kenacort A) injection on the left side after tonsillectomy and uvulopalatopharyngoplasty
Number of subjects: 48
Study 9589245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 38
Study 9589245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7819709 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdroplet insemination with sperm:oocyte ratios ranging from 2000 to 10,000 motile sperm:1 oocyte
Number of subjects: 102
Study 7819709 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdroplet insemination with sperm:oocyte ratios of 2000-4000:1 for male-factor sperm with one defect
Number of subjects: 102
Study 7819709 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdroplet insemination with sperm:oocyte ratios of 8000-10,000:1 for male-factor sperm with two or three defects
Number of subjects: 102
Study 7819709 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdroplet insemination
Number of subjects: 102
Study 7819709 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 102
Study 2644175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1350
Study 2644175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1350
Study 1151895 — intervention group
Group type: EXPERIMENTAL
Intervention: Two task-related warm-up treatments
Number of subjects: 105
Study 1151895 — intervention group
Group type: COMPARATOR
Intervention: One condition of no warm-up
Number of subjects: 105
Study 31483191 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention including an informative video, a brochure about ACP, and a guided discussion about EOL wishes
Number of subjects: 108
Study 31483191 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 108
Study 30826452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Reduction of Vascular Risk factors (IRVR) with blood pressure and cholesterol reduction
Number of subjects: 640
Study 30826452 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 640
Study 30826452 — intervention group
Group type: EXPERIMENTAL
Intervention: IRVR + EX
Number of subjects: 640
Study 30826452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 640
Study 27924779 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 137
Study 27924779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 26405668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium hyaluronate (NHA)
Number of subjects: 80
Study 26405668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid spray (ICS) 200 µg bid
Number of subjects: 80
Study 26405668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICS and NHA
Number of subjects: 80
Study 26405668 — intervention group
Group type: COMPARATOR
Intervention: Open-label nebulized saline solution (NS)
Number of subjects: 80
Study 26405668 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (NHA, ICS, ICS + NHA)
Number of subjects: 80
Study 26405668 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study 22715064 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic-resistance-training and lifestyle-activity intervention
Number of subjects: 44
Study 22715064 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 21478142 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 3 × 500 mg/day
Number of subjects: 256
Study 21478142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 21478142 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD)
Number of subjects: 256
Study 18645741 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 56
Study 18645741 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 56
Study 17052581 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of fentanyl
Number of subjects: 40
Study 17052581 — intervention group
Group type: COMPARATOR
Intervention: Infusion of alfentanil
Number of subjects: 40
Study 12608473 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial H‐II screening program
Number of subjects: 24465
Study 12608473 — intervention group
Group type: COMPARATOR
Intervention: Single FS+H‐II screening
Number of subjects: 24465
Study 10381854 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low fat diet (fat intake <=20% resting energy expenditure)
Number of subjects: 126
Study 10381854 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet from the National Cholesterol Education Program
Number of subjects: 126
Study 10381854 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting energy expenditure-fat diet + simvastatin 10mg daily
Number of subjects: 126
Study 10381854 — intervention group
Group type: COMPARATOR
Intervention: National Cholesterol Education Program step 2 diet + simvastatin 10mg daily
Number of subjects: 126
Study 8689858 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose, 100 mg t.d.s. for 16 weeks
Number of subjects: 18
Study 8689858 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 18
Study 2199743 — intervention group
Group type: EXPERIMENTAL
Intervention: myringotomy with adenoidectomy
Number of subjects: 46
Study 2199743 — intervention group
Group type: COMPARATOR
Intervention: myringotomy without adenoidectomy
Number of subjects: 46
Study 7037664 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure breathing (PEEP) during exercise
Number of subjects: 5
Study 7037664 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure breathing (PEEP) post-exercise
Number of subjects: 5
Study 7037664 — intervention group
Group type: COMPARATOR
Intervention: Normal exercise tests (control)
Number of subjects: 5
Study 31694495 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant oral suspension (125 mg)
Number of subjects: 17
Study 31694495 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant capsule (125 mg)
Number of subjects: 17
Study 28412650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus evacetrapib 130 mg
Number of subjects: 366
Study 28412650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 366
Study 28412650 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 366
Study 28412650 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg plus placebo
Number of subjects: 366
Study 25416687 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/oxaliplatin/5‐FU (TEF)
Number of subjects: 248
Study 25416687 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/oxaliplatin (TE)
Number of subjects: 248
Study 25416687 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/oxaliplatin/capecitabine (TEX)
Number of subjects: 248
Study 25416687 — intervention group
Group type: COMPARATOR
Intervention: Febrile neutropenia
Number of subjects: 248
Study 25416687 — intervention group
Group type: COMPARATOR
Intervention: Common grade 3/4 AEs
Number of subjects: 248
Study 24554598 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 48
Study 24554598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23075177 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy starting immediately at a dose of 600 mg per day
Number of subjects: 41
Study 23075177 — intervention group
Group type: COMPARATOR
Intervention: Linezolid therapy starting after 2 months at a dose of 600 mg per day
Number of subjects: 41
Study 23075177 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy at a dose of 300 mg per day after second randomization
Number of subjects: 41
Study 23075177 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy at a dose of 600 mg per day after second randomization
Number of subjects: 41
Study 23075177 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy (both dosages)
Number of subjects: 41
Study 23075177 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy
Number of subjects: 41
Study 19879595 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lactulose
Number of subjects: 28
Study 19879595 — intervention group
Group type: COMPARATOR
Intervention: 1% dextrose (control)
Number of subjects: 28
Study 17019624 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1.37 mg/day)
Number of subjects: 55
Study 17019624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15574481 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-lock containing vancomycin or ceftazidime
Number of subjects: 46
Study 15574481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15574481 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-lock
Number of subjects: 46
Study 11913107 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-total thyroidectomy
Number of subjects: 0
Study 11913107 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine radioiodide ablative therapy
Number of subjects: 0
Study 11913107 — intervention group
Group type: COMPARATOR
Intervention: Consensus guidelines
Number of subjects: 0
Study 14528702 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapies
Number of subjects: 0
Study 14528702 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study 7576677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) clonidine (loading dose of 4 micrograms/kg in 20 minutes at anesthesia induction, followed by a continuous infusion of 2 micrograms/kg/h until the end of surgery)
Number of subjects: 402
Study 7576677 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 402
Study 2895564 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) 60 mg, Imdur, once daily
Number of subjects: 70
Study 2895564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31095678 — intervention group
Group type: EXPERIMENTAL
Intervention: ASHS‐LIA (Age‐related scattered hypofluorescent spots on late‐phase indocyanine green angiography)
Number of subjects: 187
Study 31095678 — intervention group
Group type: COMPARATOR
Intervention: No ASHS‐LIA
Number of subjects: 187
Study 28385919 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HIGH: 1,103 kcal/day, 133 g protein/day)
Number of subjects: 63
Study 28385919 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein (MOD: 974 kcal/day, 84 g protein/day)
Number of subjects: 63
Study 28385919 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate‐based low protein control (CON: 1,042 kcal/day, 7 g protein/day)
Number of subjects: 63
Study 26233715 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.0‐mm locking miniplate (Group A)
Number of subjects: 30
Study 26233715 — intervention group
Group type: EXPERIMENTAL
Intervention: Single rigid 2.3‐mm plate (Group B)
Number of subjects: 30
Study 26233715 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lag screw (Group C)
Number of subjects: 30
Study 23718024 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulotoxin preparation (Disport) injected between internal and external anal sphincter portions, 90 units, 5-15 days preoperatively.
Number of subjects: 83
Study 23718024 — intervention group
Group type: COMPARATOR
Intervention: No botulotoxin injection (control group).
Number of subjects: 83
Study 21238983 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece ventilation
Number of subjects: 80
Study 21238983 — intervention group
Group type: COMPARATOR
Intervention: Self-inflating bag (SIB) ventilation
Number of subjects: 80
Study 18667054 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg 5-Loxin daily for 90 days
Number of subjects: 75
Study 18667054 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg 5-Loxin daily for 90 days
Number of subjects: 75
Study 18667054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21190858 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections combined with comprehensive rehabilitation
Number of subjects: 22
Study 21190858 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study 16201068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation of the greater omentum to the peritoneum
Number of subjects: 49
Study 16201068 — intervention group
Group type: COMPARATOR
Intervention: Non-fixation of the greater omentum
Number of subjects: 49
Study 12039463 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (n = 73) vaginally once daily
Number of subjects: 126
Study 12039463 — intervention group
Group type: COMPARATOR
Intervention: Utrogest (n = 53) vaginally three times daily (600 mg)
Number of subjects: 126
Study 10756833 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant application
Number of subjects: 0
Study 10756833 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cooperation regarding oral hygiene
Number of subjects: 0
Study 10756833 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological stability evaluation through clinical X-ray parameters
Number of subjects: 0
Study 7989980 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT and CT/MRI registration in patients infused with 10 mCi of 131I-CC49 prior to staging laparotomy
Number of subjects: 24
Study 7989980 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging following radioimmunotherapy with 131I-CC49
Number of subjects: 24
Study 3289111 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PVC)
Number of subjects: 60
Study 3289111 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 60
Study 3289111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PVC and cimetidine
Number of subjects: 60
Study 3289111 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC and cimetidine
Number of subjects: 60